Those who assumed LFB was a plodding public-sector bureaucracy may need to revise their thinking.
LFB has inked major development deals with GTC and CRXL and, with today’s announcement, has bolstered production capacity for recombinant drugs. LFB strikes me as a company that knows where it is headed and is not tentative about execution.
Market Data 
Markets 
AI
